Skip to content

Trial Summary

DREAMM7

Acronym:

DREAMM7

ACTRN/NCT /ethics:

NCT04246047

Scientific title:

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Sponsor / Cooperative group:

GlaxoSmithKline

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-05-07
Anticipated End Date2026-08-13

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Wilfrid Jaksic
Recruitment StatusNot Yet Recruiting
HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Stanley Cheung
Recruitment StatusNot Yet Recruiting